Royce & Associates LP decreased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 6.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,910,767 shares of the biopharmaceutical company’s stock after selling 124,198 shares during the quarter. Royce & Associates LP’s holdings in Catalyst Pharmaceuticals were worth $44,597,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the business. Oregon Public Employees Retirement Fund increased its position in shares of Catalyst Pharmaceuticals by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 472 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of Catalyst Pharmaceuticals by 14.0% in the third quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after acquiring an additional 498 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 3.2% in the fourth quarter. ProShare Advisors LLC now owns 22,499 shares of the biopharmaceutical company’s stock worth $525,000 after acquiring an additional 702 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Catalyst Pharmaceuticals by 7.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,080 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 714 shares in the last quarter. Finally, Navellier & Associates Inc. increased its position in shares of Catalyst Pharmaceuticals by 6.6% in the third quarter. Navellier & Associates Inc. now owns 13,346 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 822 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.
Catalyst Pharmaceuticals Stock Performance
Shares of NASDAQ:CPRX opened at $31.26 on Tuesday. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of 17.97, a price-to-earnings-growth ratio of 0.91 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $32.56. The company’s fifty day moving average is $26.97 and its two-hundred day moving average is $24.78.
Analyst Upgrades and Downgrades
Read Our Latest Report on CPRX
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.
The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).
Featured Stories
- Five stocks we like better than Catalyst Pharmaceuticals
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
